Leibowitz H M, Bartlett J D, Rich R, McQuirter H, Stewart R, Assil K
Boston University School of Medicine, Mass, USA.
Arch Ophthalmol. 1996 Aug;114(8):933-7. doi: 10.1001/archopht.1996.01100140141005.
To compare the intraocular pressure (IOP) elevating potential of 1.0% rimexolone and 0.1% fluorometholone alcohol ophthalmic suspensions in patients known to have responded to corticosteroids.
In a double-masked, randomized, single-eye, crossover protocol, corticosteroid responsiveness initially was verified in 40 asymptomatic known steroid responders by challenge with either 0.1% dexamethasone sodium phosphate or 1.0% prednisolone acetate for up to 6 weeks. After a 1-month medication washout, subjects randomly received either rimexolone or fluorometholone for 6 weeks. Medications were again discontinued for 1 month, and subjects then received the alternate drug for 6 weeks.
There was no significant difference between rimexolone and fluorometholone in the number of subjects demonstrating a 10-mm Hg increase in IOP or in the mean number of weeks required to achieve a 10-mm Hg response. Responses occurred in significantly more subjects receiving dexamethasone sodium phosphate (P = .001) or prednisolone acetate (P < .001) and in a significantly shorter interval than in subjects receiving rimexolone.
Rimexolone has a low IOP-elevating potential, comparable to that of fluorometholone and less than that of dexamethasone sodium phosphate and prednisolone acetate.
比较1.0%瑞美松龙和0.1%氟米龙醇眼药水对已知对皮质类固醇有反应的患者的眼压升高潜能。
采用双盲、随机、单眼、交叉试验方案，对40名已知的无症状皮质类固醇反应者，用0.1%磷酸地塞米松或1.0%醋酸泼尼松龙进行长达6周的激发试验，初步验证皮质类固醇反应性。在停药1个月后，受试者随机接受瑞美松龙或氟米龙治疗6周。药物再次停用1个月，然后受试者接受另一种药物治疗6周。
在眼压升高10mmHg的受试者数量或达到10mmHg反应所需的平均周数方面，瑞美松龙和氟米龙之间无显著差异。接受磷酸地塞米松（P = 0.001）或醋酸泼尼松龙（P < 0.001）的受试者反应明显更多，且反应间隔明显短于接受瑞美松龙的受试者。
瑞美松龙升高眼压的潜能较低，与氟米龙相当，低于磷酸地塞米松和醋酸泼尼松龙。
